These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21307076)

  • 21. Tolerance to Proinsulin-1 Reduces Autoimmune Diabetes in NOD Mice.
    Jhala G; Selck C; Chee J; Kwong CJ; Pappas EG; Thomas HE; Kay TWH; Krishnamurthy B
    Front Immunol; 2021; 12():645817. PubMed ID: 33841427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral delivery of single-chain insulin (SCI-59) analog by bacterium-like particles (BLPs) induces oral tolerance and prevents autoimmune diabetes in NOD mice.
    Mao R; Chen Y; Wu Q; Zhang T; Diao E; Wu D; Wang M; Liu Y; Lu L; Chang X; Zheng Y; Wang Y
    Immunol Lett; 2019 Oct; 214():37-44. PubMed ID: 31473255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes.
    Tian J; Atkinson MA; Clare-Salzler M; Herschenfeld A; Forsthuber T; Lehmann PV; Kaufman DL
    J Exp Med; 1996 Apr; 183(4):1561-7. PubMed ID: 8666914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group.
    Skyler JS; Rabinovitch A
    J Diabetes Complications; 1992; 6(2):77-88. PubMed ID: 1611143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of morning fasting blood glucose variability with insulin antibodies and clinical factors in type 1 diabetes.
    Yoneda C; Tashima-Horie K; Fukushima S; Saito S; Tanaka S; Haruki T; Ogino J; Suzuki Y; Hashimoto N
    Endocr J; 2016 Jul; 63(7):603-9. PubMed ID: 27170092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4+CD25+ regulatory T cells generated in response to insulin B:9-23 peptide prevent adoptive transfer of diabetes by diabetogenic T cells.
    Mukherjee R; Chaturvedi P; Qin HY; Singh B
    J Autoimmun; 2003 Nov; 21(3):221-37. PubMed ID: 14599847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term subcutaneous insulin treatment delays but does not prevent diabetes in NOD mice.
    Brezar V; Culina S; Gagnerault MC; Mallone R
    Eur J Immunol; 2012 Jun; 42(6):1553-61. PubMed ID: 22678909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control.
    Chaillous L; Bouhanick B; Kerlan V; Mathieu E; Lecomte P; Ducluzeau PH; Delamaire M; Sonnet E; Maugendre D; Maréchaud R; Rohmer V; Saï P; Charbonnel B
    Diabetes Metab; 2010 Feb; 36(1):64-70. PubMed ID: 20060765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.
    Hanley AJ; Zinman B; Sheridan P; Yusuf S; Gerstein HC;
    Diabetes Care; 2010 Mar; 33(3):608-13. PubMed ID: 20009095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gamma delta T cells as mediators of mucosal tolerance: the autoimmune diabetes model.
    Hänninen A; Harrison LC
    Immunol Rev; 2000 Feb; 173():109-19. PubMed ID: 10719672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells.
    Ploix C; Bergerot I; Durand A; Czerkinsky C; Holmgren J; Thivolet C
    Diabetes; 1999 Nov; 48(11):2150-6. PubMed ID: 10535448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment.
    Cabrera-Rode E; Perich P; Diaz-Horta O; Tiberti C; Molina G; Arranz C; Martin JM; Licea M; De Leiva AD; Puig-Domingo M; Dimario U
    Autoimmunity; 2002 Nov; 35(7):469-74. PubMed ID: 12685875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus.
    Kudolo GB
    J Clin Pharmacol; 2001 Jun; 41(6):600-11. PubMed ID: 11402628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells.
    Augstein P; Dunger A; Heinke P; Wachlin G; Berg S; Hehmke B; Salzsieder E
    Biochem Biophys Res Commun; 2003 May; 304(2):378-84. PubMed ID: 12711326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes.
    Goel A; Chiu H; Felton J; Palmer JP; Brooks-Worrell B
    Diabetes; 2007 Aug; 56(8):2110-5. PubMed ID: 17473222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
    Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
    Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide.
    Alleva DG; Gaur A; Jin L; Wegmann D; Gottlieb PA; Pahuja A; Johnson EB; Motheral T; Putnam A; Crowe PD; Ling N; Boehme SA; Conlon PJ
    Diabetes; 2002 Jul; 51(7):2126-34. PubMed ID: 12086942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA).
    Li X; Liao L; Yan X; Huang G; Lin J; Lei M; Wang X; Zhou Z
    Diabetes Metab Res Rev; 2009 Jul; 25(5):411-6. PubMed ID: 19488999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.